Orion Infusion Limited (DSE:ORIONINFU)

Market Cap	7.27B
Revenue (ttm)	631.54M
Net Income (ttm)	35.63M
Shares Out	20.36M
EPS (ttm)	1.75
PE Ratio	204.05
Forward PE	n/a
Dividend	2.00 (0.56%)
Ex-Dividend Date	Dec 2, 2025

Volume	455,721
Average Volume	284,575
Open	340.10
Previous Close	341.70
Day's Range	340.10 - 357.80
52-Week Range	303.30 - 587.50
Beta	-2.52
RSI	36.47
Earnings Date	Jan 29, 2026

About Orion Infusion

Orion Infusion Limited manufactures and sells large volume parenteral and other lifesaving injectable products in Bangladesh. The company offers I.V. rehydration, electrolyte, and acidosis solutions; ranitidine I.V. infusion; anti-microbial products; metronidazole I.V; pure steam generated fluids; and amino acids solution. It also provides sterile and nonpyrogenic solution, such as Dextrolac, Dianak, Hartman, Manisol, Plasmasol, and Proliv; hypertonic solution, including Dextrosal, Electrodex-10, Fructose – 10, Orlev, Ortac; Dextropac, an isoto...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 563
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ORIONINFU

Financial Performance

In 2025, Orion Infusion's revenue was 664.92 million, a decrease of -19.64% compared to the previous year's 827.42 million. Earnings were 35.02 million, a decrease of -17.27%.